Vetter Continues to Expand Capacity

Vetter Continues to Expand Capacity

Structural work completed on Vetter's new multi-functional building for its Development Service and information technology (IT)

Ravensburg, Germany, January 30, 2015 / B3C newswire / – Following 16 months of construction, the first phase of a modern, multi-functional building at Vetter's Ravensburg Schuetzenstrasse site has been completed. Estimated to be fully operational by the beginning of 2016, the new facility will contain high-tech laboratories and workplaces for Vetter Development Service, as well as a highly secure data center and additional office space for a total area of 8,500 sqm. The 26 million Euro investment is a direct result of increased demand by customers for support in drug development, as well as the need for enhanced company-wide IT systems to meet future requirements already being seen today.

Through facilities located in Chicago, USA, and Ravensburg, Germany, Vetter Development Service offers its customers support in all phases of clinical drug development, including pharmaceutical analysis, process development, and clinical trial supply. Due to increased demand by customers for these services over the past several years, the company has made the commitment to invest in a new building at its Schuetzenstrasse facility. The six-story building will contain laboratory space for performing microbiological analysis, and will also have sufficient spare capacity to meet future growth needs such as additional cleanrooms and labs.

The multi-functional building is also an investment in future-oriented IT systems which help Vetter meet the ever-increasing quality and security needs of customers and regulatory authorities alike. For example the new data center will have enhanced security systems and a safety cell that protects technology and data from external physical hazards, as well as a state-of-the-art gas extinguishing system to minimize damage in the event of an emergency.

"With this new building, we are addressing the growing demand of our customers in the area of clinical drug development and manufacturing," says Thomas Otto, a Vetter Managing Director. "Furthermore, with the installation of the sophisticated IT systems, Vetter will be well-prepared to meet future challenges that present themselves."

About Vetter
Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO's extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of product approvals for novel bio/ pharmaceutical compounds. Since 2014, Vetter operates a representative office in Singapore, increasing the presence of the company and the awareness of its service portfolio in the Asian healthcare market.


Vetter Pharma International GmbH
Oskar Gold
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3729
E-mail: [email protected]